Micro Typing Systems A/B; MTS A/B/D; MTS A/B/D/Reverse and MTS Monoclonal Rh Phenotype Card
The FDA has updated documentation regarding the manufacture of several specific diagnostic products by Micro Typing Systems, including the Monoclonal Rh Phenotype Card and various MTS A/B/D card configurations.
This update affects Micro Typing Systems and personnel involved in the manufacturing, regulatory compliance, and quality control of blood grouping reagents and monoclonal phenotype cards.
The mention of manufacturing for these specific blood typing products suggests a potential update to the establishment's production status or site-specific manufacturing data. For regulatory professionals, this underscores the necessity of maintaining accurate manufacturing records for monoclonal-based diagnostic reagents, which are critical for ensuring blood compatibility and patient safety in transfusion medicine.
Regulatory and manufacturing teams should review current technical files for site-specific production processes. Quality units must ensure that manufacturing changes for blood grouping reagents remain aligned with validated monoclonal antibody protocols and existing FDA-approved dossiers.